Valuation: Arctic Bioscience

Market Cap 80.87M 8.51M 7.38M 6.91M 6.3M 11.86M 812M 12.06M 80.98M 31.73M 406M 31.96M 31.27M 1.36B P/E 2026 *
-3.37x
P/E 2027 * -
Enterprise Value 147M 15.46M 13.4M 12.54M 11.44M 21.54M 1.47B 21.9M 147M 57.62M 738M 58.05M 56.78M 2.46B EV / Sales 2026 *
2.53x
EV / Sales 2027 * -
Free-Float
47.75%
Yield 2026 *
-
Yield 2027 * -
1 day+1.67%
1 week-3.17%
Current month+14.23%
1 month-6.15%
3 months+1.67%
6 months-10.03%
Current year-7.01%
1 week 2.82
Extreme 2.82
3.29
1 month 2.51
Extreme 2.51
3.4
Current year 2.51
Extreme 2.51
3.67
1 year 2.51
Extreme 2.51
4.65
3 years 1.65
Extreme 1.65
16.8
5 years 1.65
Extreme 1.65
21.7
10 years 1.65
Extreme 1.65
32
Manager TitleAgeSince
Chief Executive Officer 60 2010-12-31
Chief Executive Officer 54 2022-02-28
Director of Finance/CFO 47 2022-03-31
Director TitleAgeSince
Chairman 68 2015-11-30
Director/Board Member 55 2014-12-31
Director/Board Member 46 2020-12-31
Date Insider Type Main position Quantity % Market Cap.
4/24/23 Buy

Director

943,833 3.8641%
4/24/23 Buy

Director

943,833 3.8641%
2/23/23 Buy

Chief Technology Officer

11,500 0.0472%
Change 5-day change 1-year change 3-year change Capi.($)
+1.67%-3.17%-10.29%-69.44% 8.51M
-0.72%+3.16%+88.73%+124.31% 1,083B
-0.38%+0.04%+49.15%+48.58% 626B
-0.65%+0.91%+25.07%+63.15% 442B
-1.26%-0.55%+47.20%+36.95% 363B
-1.36%-0.45%+28.75%+36.27% 295B
-1.06%-2.76%+5.57%+5.31% 248B
+0.07%+1.21%+44.84%+58.16% 224B
-2.71%+1.38%-6.91%-51.82% 210B
+0.43%+2.90%+12.97%+69.80% 168B
Average -0.45%+4.31%+28.51%+32.13% 365.91B
Weighted average by Cap. -0.64%+4.29%+48.02%+63.48%

Financials

2026 *2027 *
Net sales 58M 6.11M 5.29M 4.95M 4.52M 8.5M 582M 8.65M 58.08M 22.76M 291M 22.92M 22.42M 972M -
Net income -24M -2.53M -2.19M -2.05M -1.87M -3.52M -241M -3.58M -24.03M -9.42M -121M -9.49M -9.28M -402M -
Net Debt 66M 6.95M 6.02M 5.64M 5.14M 9.68M 663M 9.84M 66.09M 25.89M 332M 26.09M 25.52M 1.11B -
Logo Arctic Bioscience
Arctic Bioscience AS is a Norway-based biotech company developing and commercializing both pharmaceutical and nutraceutical products based on the properties of herring roe oil. Arctic Bioscience’s purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The Company is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The Company's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.
Employees
19
Date Price Change Volume
26-08-12 NOK 3.050 +1.67% 10,438
26-08-11 NOK 3.000 -1.96% 22,780
26-08-10 NOK 3.060 -2.86% 6,869
26-08-07 NOK 3.150 +2.94% 6,970
26-08-06 NOK 3.060 -2.86% 11,564
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Annual profits - Rate of surprise